phase II study high-dose continuous infusion lymphokine-activated killer cells patients metastatic melanoma Thirty-three patients metastatic melanoma phase II study intravenous continuous infusion IVCI lymphokine-activated killer LAK cells dose optimal priming dose LAK-cell induction LAK-cell dose IVCI schedule previous phase trial CI schedule evaluation postulated reduction toxicity possibility prolonged infusion rebound lymphocytosis LAK-cell generation dose schedule patients similar age performance status sites disease previous trials patients assessable response toxicity patient partial response months duration significant responses Significant toxicity hypotension pressors dyspnea renal insufficiency hepatic dysfunction cardiac arrhythmias toxicities cessation infusion deaths first days treatment infection central line LAK cells tumor tumor-related hemorrhage Toxicity high comparable previous studies high-dose IV bolus schedule IVCI schedule high-dose bolus LAK cells nonrandomized sequential studies patients advanced melanoma CI efficacious 